Abstract
XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can bind the estrogen response element (ERE) sequence to block ER-ERE binding and inhibit ERα activities, which may be useful for overcoming drug resistance to currently available antiestrogen treatments. This review discusses the progress relating to the structure and function studies of specific DNA recognition of XR5944. The sites of intercalation within a native promoter sequence appear to be different from the ideal binding site and are context- and sequence- dependent. The structural information may provide insights for rational design of improved EREspecific XR5944 derivatives, as well as of DNA bis-intercalators in general.
Keywords: Anticancer drug, DNA bis-intercalation, DNA bis-intercalation with major groove binding, NMR solution structure, XR5944 or MLN944.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944
Volume: 15 Issue: 14
Author(s): Clement Lin and Danzhou Yang
Affiliation:
Keywords: Anticancer drug, DNA bis-intercalation, DNA bis-intercalation with major groove binding, NMR solution structure, XR5944 or MLN944.
Abstract: XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can bind the estrogen response element (ERE) sequence to block ER-ERE binding and inhibit ERα activities, which may be useful for overcoming drug resistance to currently available antiestrogen treatments. This review discusses the progress relating to the structure and function studies of specific DNA recognition of XR5944. The sites of intercalation within a native promoter sequence appear to be different from the ideal binding site and are context- and sequence- dependent. The structural information may provide insights for rational design of improved EREspecific XR5944 derivatives, as well as of DNA bis-intercalators in general.
Export Options
About this article
Cite this article as:
Lin Clement and Yang Danzhou, DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944, Current Topics in Medicinal Chemistry 2015; 15 (14) . https://dx.doi.org/10.2174/1568026615666150413155608
DOI https://dx.doi.org/10.2174/1568026615666150413155608 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
IBD Modern Concepts, Nano Drug Delivery and Patents: An Update
Recent Patents on Nanomedicine A Comparative Study of Glucose and Fructose in the Development of Sarcoma 180 in Mice
Letters in Organic Chemistry Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets Structural Design and Physicochemical Foundations of Hydrogels for Biomedical Applications
Current Medicinal Chemistry Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Defective Insulin Signalling, Mediated by Inflammation, Connects Obesity to Alzheimer Disease; Relevant Pharmacological Therapies and Preventive Dietary Interventions
Current Alzheimer Research The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies
Current Pharmacogenomics and Personalized Medicine Acridine Derivatives as Chemotherapeutic Agents
Current Medicinal Chemistry Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences CD248: Reviewing its Role in Health and Disease
Current Drug Targets The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Novel Nanotechnology Approaches for Targeted Cancer Therapy
Recent Patents on Nanomedicine Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology The Pharmacological Treatment of Cachexia
Current Drug Targets Biogenic Silver and Zero-Valent Iron Nanoparticles by Feijoa: Biosynthesis, Characterization, Cytotoxic, Antibacterial and Antioxidant Activities
Anti-Cancer Agents in Medicinal Chemistry